Repligen (RGEN) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revolution Medicines (RVMD) has outperformed Repligen (RGEN) over the past year, gaining 298.5% versus a gain of 16.8%. Over five years, RVMD leads with a +604.1% price change compared with -34.9% for RGEN. Revolution Medicines is the larger company by market cap ($40.67 billion vs $11.04 billion), about 3.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGEN | RVMD |
|---|---|---|
| Share price | $173.88 | $189.76 |
| Market cap | $11.04B | $40.67B |
| 1-day change | +6.13% | +0.87% |
| YTD return | +6.11% | +138.24% |
| 1-year return | +16.85% | +298.53% |
| 5-year return | -34.86% | +604.12% |
| P/E ratio (TTM) | 225.82 | — |
| Forward P/E | 65.68 | — |
| EPS (TTM) | $0.77 | $-8.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $738.26M | $0 |
| Revenue growth (YoY) | +16.36% | — |
| Net income (latest FY) | $48.89M | $-1.13B |
| Gross margin | 52.32% | — |
| Operating margin | 7.47% | — |
| Net margin | 6.62% | — |
| 52-week high | $198.87 | $224.31 |
| 52-week low | $100.99 | $47.28 |
| Distance from 52-week high | -12.57% | -15.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +12.12% | +36.40% |
| Average volume | 1.18M | 1.93M |
| Shares outstanding | 63.49M | 214.34M |
| Employees | 2,000 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revolution Medicines is about 3.7 times larger than Repligen by market value ($40.67B vs $11.04B).
- RVMD has outperformed RGEN by 281.7 percentage points over the past year.
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
RGEN vs RVMD FAQ
Which is bigger, Repligen or Revolution Medicines?
Revolution Medicines (RVMD) is larger, with a market capitalization of $40.67B compared with $11.04B for Repligen (RGEN).
Which stock has performed better over the past year, RGEN or RVMD?
RVMD returned +298.53% over the past 12 months, compared with +16.85% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Are Repligen and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.